Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma as Front Line Therapy

IRB/UVA Tracking #
20241
Contact
Erica Stallard
Contact Email
Contact Phone
Phase
II
Primary purpose
Treatment
Cancer PI
Craig Portell
Status
OPEN TO ACCRUAL
Ages
Adult